Conventional siRNA therapeutics are mostly delivered to the liver, limiting their therapeutic applications. In contrast, SAMiRNA® enables selective delivery to cancer and inflammatory tissues as well as the liver after systemic administration. This innovative delivery platform overcomes existing limitations, providing new treatment options for a wide range of intractable diseases including fibrosis, cancer, and immune disorders.